This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

### Populations
- **Individuals:** With adolescent idiopathic scoliosis

### Interventions
- Interventions of interest are:
  - Clinical management with prognostic testing using an algorithm incorporating single-nucleotide variant-based testing

### Comparators
- Comparators of interest are:
  - Routine clinical management (radiologic and clinical follow-up)

### Outcomes
- Relevant outcomes include:
  - Symptoms
  - Morbid events
  - Change in disease status

## DESCRIPTION

Adolescent idiopathic scoliosis (AIS) is a disease of unknown etiology that causes mild-to-severe spinal deformity in approximately 1% to 3% of adolescents. While there is controversy about the value of screening and treatment, once diagnosed, patients are frequently closely followed. In cases with significant progression of curvature, both medical (bracing) and surgical (spinal fusion) interventions are considered. The ScoliScore AIS prognostic DNA-based test uses an algorithm incorporating results of testing for 53 single nucleotide variants (SNVs), along with the patient’s presenting spinal curve (Cobb angle), to generate a risk score (range, 1-200), which can be used qualitatively or quantitatively to predict the likelihood of spinal curve progression.

## SUMMARY OF EVIDENCE

For individuals with AIS who receive clinical management with prognostic testing using an algorithm incorporating SNV-based testing, the evidence includes cross-sectional studies reporting on the clinical validity of the ScoliScore test, along with cross-sectional studies reporting on the association between SNVs in various genes and scoliosis progression. The relevant outcomes are symptoms, morbid events, and change in disease status. A single study on the clinical validity for the ScoliScore AIS prognostic DNA-based test has reported a high negative predictive value for ruling out the possibility of progression to severe curvature in a population with a low baseline likelihood of progression. It is not clear if the increase in predictive accuracy provided by testing is statistically or clinically meaningful. Other genetic studies have not demonstrated significant associations between the SNVs used in the ScoliScore and scoliosis progression. Studies have identified additional SNVs that may be associated with AIS severity, but these associations have not been reliably replicated. The clinical validity of DNA-based testing (either through testing of individual SNVs or an algorithm incorporating SNV results) for predicting...
scoliosis progression in patients with AIS has not been established. There is no direct evidence demonstrating that use of this test results in changes in management that improve outcomes. The value of early identification and intervention(s) for people at risk for progression of the disease and whether laboratory testing improves disease identification beyond clinical evaluation are unknown. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

DNA-based prognostic testing for adolescent idiopathic scoliosis is considered investigational.

POLICY GUIDELINES

GENETIC COUNSELING

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

MEDICARE ADVANTAGE

For Medicare Advantage DNA-based prognostic testing for adolescent idiopathic scoliosis is unlikely to impact therapeutic decision-making in the clinical management of the patient and is considered not medically necessary.

BACKGROUND

ADOLESCENT IDIOPATHIC SCOLIOSIS

AIS is the most common pediatric spinal deformity, affecting 1% to 3% of adolescents. This disease, of unknown etiology, occurs in otherwise healthy children with the onset of, and highly correlated with, the adolescent growth spurt. The vertebrae become misaligned such that the spine deviates from the midline laterally and rotates axially. The deviation can occur anteriorly (a lordotic deviation), posteriorly (a kyphotic deviation), or laterally. Although AIS affects females and males in a nearly 1:1 ratio, progression to severe deformity occurs more often in females. Because the disease can have a rapid onset and produce considerable morbidity, school screenings have been recommended. However, screening remains somewhat controversial, with conflicting guidelines supporting and not supporting this practice.

Diagnosis

Diagnosis is established by radiologic observation in adolescents (age ten years until the age of skeletal maturity) of a lateral spine curvature of 10° or more, as measured using the Cobb angle. The Cobb angle is defined as the angle measured between the maximally tilted proximal and distal vertebrae of the curve. The curvature is considered mild (<25°), moderate (25°-40°), or severe (>40°) in a patient still growing. Once diagnosed, patients must be monitored over several years, usually with serial radiographs for curve progression.
Treatment

If the curve progresses, spinal bracing is the generally accepted first-line treatment. If the curve progresses in spite of bracing, spinal fusion may be recommended.

Curve progression has been linked to a number of factors, including sex, curve magnitude, patient age, and skeletal maturity. Risk tables, by Lonstein and Carlson (1984)\(^3\), and Peterson and Nachemson (1995),\(^4\) help in triage and treatment decision making about patients with AIS. Tan et al (2009) compared a broad array of factors and concluded that using 30° as an endpoint, initial Cobb angle magnitude produces the best prediction of progression outcome.\(^5\)

Genetic Associations and Scoliosis

The familial nature of this disease was noted as early as 1968.\(^6\) About one-quarter of patients report a positive family history of the disease, and twin studies have consistently supported shared genetic factors.\(^1\) Genome-wide linkage studies have reported multiple chromosomal regions of interest, often not replicated. Ogilvie (2010) has suggested AIS is a complex polygenic trait.\(^7\) Ogilvie et al (2010) at Axial Diagnostics published a study evaluating an algorithm using 53 single nucleotide variant (SNV) markers identified from unpublished genome-wide association studies to differentiate patients unlikely to exhibit severe progression in curvature from those at considerable risk for severe progression. The clinical validity of this assay was reported in a 2010 retrospective case-control cohort study using this algorithm.\(^2\)

ScoliScore AIS

The ScoliScore AIS prognostic DNA-based test (Transgenomic), which uses an algorithm incorporating results of testing for 53 SNVs, along with the patient’s presenting spinal curve (Cobb angle), to generate a risk score (range, 1-200), can be used qualitatively or quantitatively to predict the likelihood of spinal curve progression. The test is intended for white (Caucasian) patients, ages nine to 13 years, with a primary diagnosis of AIS with a mild scoliotic curve (defined as <25°).

The development and validation of the ScoliScore SNV-based prognostic algorithm were described by Ward et al (2010) in the industry-sponsored study discussed above.\(^2\) The prognostic algorithm was developed in a cohort of 2192 female patients from prior studies. Candidate genes were selected based on previous genome-wide association studies data from the same investigators. The independent effect of each SNV and clinical factors (initial Cobb angle) and all gene-gene interaction terms were tested in a stepwise logistic regression using a backward-selection procedure and then using a forward-selection procedure. The final predictive model included 53 SNV markers, multiple gene-gene interaction terms, and the patient’s initial Cobb angle. Prediction probabilities were converted to a numeric score ranging from one to 200. A priori, low-risk of progression was determined to be less than 1%; from the generation cohort, a score of less than 41 was selected as an initial cutoff.

The ScoliScore™ AIS Prognostic Test was originally developed by Axial Biotech with test rights acquired by Transgenomic in 2013. In 2015, Transgenomic divested its Genetic Assays & Platforms Business Unit to ADSTEC Corp.\(^8\) In June 2017, Transgenomic was acquired by Precipio Diagnostics in a reverse merger transaction.\(^9\) It does appear that the test remains commercially available.

**REGULATORY STATUS**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.
Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.


24. National Government Services, Inc. (Primary Geographic Jurisdiction 06 & K - Illinois, Minnesota, Wisconsin, Connecticut, New York - Entire State, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont) LCD for Molecular Pathology Procedures (L35000), Revision Effective Date for services performed on or after 01/01/2019.